Published: Wed, January 11, 2017
Economy | By Melissa Porter

Japan's Takeda Buys US Cancer Drug Maker Ariad for $5.2 Billion

Japan's Takeda Buys US Cancer Drug Maker Ariad for $5.2 Billion

While the stock price moved along with the volume change, shares are touching $23.72 at the time of writing.

Investors interested in trading ARIA stock at the current market price of $13.74/share should know the company will next release quarterly results for the December 2017 quarter. Bearish revenue estimates established at $42.5M while the bullish revenue forecast has been figured out at $58.8M. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is 10.45 percent while its Performance (Week) is 10.81 percent and Performance (month) is at 0.37 percent. The firm owned 128,964 shares of the pharmaceutical company's stock after selling 1,732 shares during the period. Brigatinib, an investigational drug product with peak annual sales potential of over $1 billion, will generate significant long-term value for Takeda.

The company's quick ratio for most recent quarter is 3.20 along with current ratio for most recent quarter of 3.20. (NASDAQ:ARIA)'s stock about -0.40% from the 50-day high and 174.80% away from the 50-day low. They expect $-0.17 earnings per share, up 46.88% or $0.15 from last year's $-0.32 per share.

TRADEMARK VIOLATION WARNING: "ARIAD Pharmaceuticals, Inc". For the past month, ARIAD Pharmaceuticals, Inc.'s stock has been 86.13%, 77.24% for the last quarter, 222.25% for the past six months and 346.43% for the past 52 weeks. ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA)'s EPS growth this year is -40.80% and the trailing 12-month EPS is $-0.18. (NASDAQ:ARIA) traded up 2.54% during trading on Friday, reaching $13.74. Now shares have been rated as "Buy" from 3 Analysts.

Image: Takeda agrees to acquire Ariad Pharmaceuticals for $5.2bn. They set a "hold" rating and a $9.50 price target for the company.

According to Zacks Investment Research, "Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology". 2 said it's a Buy, 4 assigned Hold rating where 2 stated the stock as Underperform and 0 marked the stock as Sell.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company.

Japanese drugmakers are facing pressure in their home market as the government tries to cut prices of many branded medicines and put a greater focus on cheaper generics to rein in its health spending. Beyond Iclusig and brigatinib, Ariad's commitment and expertise in targeted kinase inhibition linked to strong translational science generated further pipeline opportunities which provide additional long-term upside potential.

Ariad specializes in developing therapies for patients with rare forms of chronic and acute blood cancer leukemia, lung cancer and other rare cancers.

Like this: